Episode 2 - Overcoming Barriers to Prescribing: A Med Table Talk™: Targeted Therapy in Atopic Dermatitis Series

Estimated Time
0.75 hr

Release Date
Apr 29, 2022

Expiration Date
Sep 01, 2023

In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.
 
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated.

Speakers

Accreditation and Disclosure Information

Target Audience
This CE activity is intended for dermatologists and allergists who are involved in the care and treatment of patients with atopic dermatitis.
 
Educational Objectives
After completing this CE activity, the participant should be better able to:
  • Assess the mechanistic rationale for the benefit and risk profiles of targeted therapies such as JAK inhibitors, including varying rates of AEs (eg, herpes zoster, serious infections, VTE, cytopenias
  • Plan strategies to enhance care of individuals with AD, including patients of diverse backgrounds
Accreditation, Support and Credit
JointLogoIn support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
 
 
Support Statement
This CE activity is supported by an educational grant from Pfizer.
 
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 
 
Faculty Disclosures
Planner/Presenter
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
 
Neal Bhatia, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, Inc., Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, EPI Health, Ferndale Pharma Group, Foamix Pharmaceuticals Ltd., Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Pharmaceuticals Corp, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Stemline Therapeutics, Sun Pharma, and VYNE Therapeutics Inc.
Speakers’ Bureau with AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, Inc., Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, EPI Health, Ferndale Pharma Group, Foamix Pharmaceuticals Ltd., Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Pharmaceuticals Corp, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Stemline Therapeutics, Sun Pharma, and VYNE Therapeutics Inc.
Research Grant from Arcutis Biotherapeutics, Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, Galderma, LEO Pharma, Lilly, and Ortho Pharmaceuticals Corp.
 
Planner/Presenter
Sakina S. Bajowala, MD, FAAAAI     
Board-Certified Allergist & Immunologist
Kaneland Allergy & Asthma Center
North Aurora, IL
 
Sakina S. Bajowala, MD, FAAAAI, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Solid Starts LLC.
Independent Contractor for Novartis Pharmaceuticals Corporation.
Other with Wise Prince, LLC – owner (healthcare software).
 
Planner/Presenter
Temitayo A. Ogunleye, MD
Associate Professor and Associate Director of  Diversity, Equity and Inclusion
University of Pennsylvania Department of Dermatology
Philadelphia, PA
 
Temitayo A. Ogunleye, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Janssen Pharmaceuticals.
 
Presenter
Thomas B. Casale, MD
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics 
Director, Division of Allergy and Immunology 
Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL
 
Thomas B. Casale, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Sanofi Genzyme/Regeneron Pharmaceuticals.
Research Grant from Sanofi Genzyme/Regeneron Pharmaceuticals.
Speakers’ Bureau with Sanofi Genzyme/Regeneron Pharmaceuticals.
 
Presenter
Adelaide A. Hebert, MD
Professor of Dermatology and Pediatrics
UTHealth McGovern Medical School
Chief of Pediatric Dermatology
UTHealth McGovern Medical School and
Children's Memorial Hermann Hospital
Houston, TX
 
Adelaide A. Hebert, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Arcutis Biotherapeutics, Almirall, Castle Bioscience, Galderma, Incyte, LEO Pharma, Ortho Dermatologics, and Pfizer.
Research Grant from AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, LEO Pharma, Pfizer, and UCB.  (All research funds paid to institution)
Speakers’ Bureau with Arcutis Biotherapeutics, Almirall, Castle Bioscience, Galderma, Incyte, LEO Pharma, Ortho Dermatologics, and Pfizer.
Other: Data Safety Monitoring Board with GlaxoSmithKline, Ortho Dermatology (Bausch), and Sanofi Genzyme/Regeneron Pharmaceuticals,
 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
 
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

 

Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved